Immune-inflammatory markers in remission after a first-episode psychosis in young patients

Zozulya S.A.; Tikhonov D.V.; Kaleda V.G.; Klyushnik T.P.

doi:https://doi.org/10.17116/jnevro202112106159

Zozulya S.A.

Mental Health Research Center

ORCID: 0000-0001-5390-6007

Tikhonov D.V.

Mental Health Research Center

SPIN RSCI: 6093-8619
Scopus AuthorID: 57195277873
ResearcherID: AAD-4447-2022
ORCID: 0000-0003-3001-7842

Kaleda V.G.

Mental Health Research Centre

SPIN RSCI: 9035-3290
Scopus AuthorID: 56765570100
ResearcherID: K-5466-2013
ORCID: 0000-0002-1209-1443

Klyushnik T.P.

Mental Health Research Center

ORCID: 0000-0001-5148-3864

Immune-inflammatory markers in remission after a first-episode psychosis in young patients

Authors:

Zozulya S.A., Tikhonov D.V., Kaleda V.G., Klyushnik T.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6): 59‑66

DOI: 10.17116/jnevro202112106159

Read: 1909 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zozulya SA, Tikhonov DV, Kaleda VG, Klyushnik TP. Immune-inflammatory markers in remission after a first-episode psychosis in young patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6):59‑66. (In Russ.)
https://doi.org/10.17116/jnevro202112106159

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study clinical, psychopathological and immunological features of remission after first-episode psychosis in young patients to determine the patterns of this stage and the possibility of using the results for monitoring, prognosis and optimization of therapy.

MATERIAL AND METHODS

Fifty patients, aged 15—25 years, mean age 20.8±2.2 years, experiencing first-episode psychosis (F20, F25) and 45 healthy age-matched young men (mean age 19.2±3.2 years) were examined. The average age of psychosis manifestation was 19.8±2.5 months. Clinical, psychopathological, psychometric (PANSS and HDRS) and immunological («Neuro-immuno-test» technology) examinations were carried out at the psychotic state, during period of psychopathological symptoms reduction and further for 1—2 years until complete/significant reduction of psychotic symptoms.

RESULTS

Three stages of remission are revealed: I — the stage of reduction and modification of leading psychotic symptoms, II — the stage of stabilization of mental functions, III — the stage of reintegration of mental functions. It has been shown that each stage corresponds to different features of clinical symptoms and also certain spectra of immune markers (activity of leukocyte elastase, α1-proteinase inhibitor and level of autoantibodies to S100-B and OBM proteins) in blood serum of patients. The differences in the spectra of immune parameters at the second stage of remission in patients with affective (depressive) disorders define various patterns of post-psychotic development of disease. The most representative are immunological features of the third stage of remission.

CONCLUSION

The dynamics of immune markers in the course of remission can be considered as a biological criterion for assessment of the outcome of the first first-episode psychosis and the completeness of remission.

Keywords:

schizophrenia

first-episode psychosis

remission

young adult age

inflammatory and autoimmune markers

Authors:

Zozulya S.A.

Mental Health Research Center

ORCID: 0000-0001-5390-6007

Tikhonov D.V.

Mental Health Research Center

SPIN RSCI: 6093-8619
Scopus AuthorID: 57195277873
ResearcherID: AAD-4447-2022
ORCID: 0000-0003-3001-7842

Kaleda V.G.

Mental Health Research Centre

SPIN RSCI: 9035-3290
Scopus AuthorID: 56765570100
ResearcherID: K-5466-2013
ORCID: 0000-0002-1209-1443

Klyushnik T.P.

Mental Health Research Center

ORCID: 0000-0001-5148-3864

Received:

08.07.2020

Accepted:

27.07.2020

Close metadata

References:

Kaleda VG. Endogenous psychoses with a first episode at the juvenile age: course and outcome (follow-up study). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(9):11-23. (In Russ.).
Cohen D, Flament M, Dubos PF, Basquin M. Case series catatonic syndrome in young people. J Am Acad Child Adolesc Psychiatry. 1999;38(8):1040-1046. https://doi.org/10.1097/00004583-199908000-00021
Klyushnik TP, Zozulya SA, Androsova LV, Sarmanova ZV, Otman IN, Dupin AM, Panteleeva GP, Oleichik IV, Abramova LI, Stolyarova SA, Shipilova ES, Borisova OA. Immunological monitoring of endogenous paroxysmal psychoses. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(2):37-41. (In Russ.).
Kogan S, Ospina LH, Kimhy D. Inflammation in individuals with schizophrenia — implications for neurocognition and daily function. Brain Behav Immun. 2018;74:296-299. https://doi.org/10.1016/j.bbi.2018.09.016
Brusov OS, Oleichik IV, Faktor MI, Karpova NS, Sizov SV, Yunilaynen OA. Thrombodynamic parameters of hypercoagulability in patients with affective disorder and schizophrenia in a state of exacerbation. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;10:53-57. (In Russ.). https://doi.org/10.17116/jnevro201811810153
Misiak B, Frydecka D, Stanczykiewicz B, Samochowiec J. Editorial: Peripheral markers of immune response in major psychiatric disorders: where are we now and where do we want to be? Front Psychiatry. 2019;10:5. https://doi.org/10.3389/fpsyt.2019.00005
Pedraz-Petrozzi B, Elyamany O, Rummel C, Mulert C. Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review. J Neuroinflammation. 2020;15:17(1):56. https://doi.org/10.1186/s12974-020-1721-z
Hafizi S, Tseng HH, Rao N, Selvanathan T, Kenk M, Bazinet RP, Suridjan I, Wilson AA, Meyer JH, Remington G, Houle S, Pablo M, Rusjan PM, Mizrahi R. Imaging microglial activation in untreated first-episode psychosis: a PET study with [18F]FEPPA. Am J Psychiatry. 2017;174(2):118-124. https://doi.org/10.1176/appi.ajp.2016.16020171
Androsova LV, Kaleda VG, Barkhatova AN, Tsutsulkovskaya MYa, Kolyaskina GK. The effect of trearment on interleukin-1β production in patients with first episode of juvenile psychosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2007;9:50-54. (In Russ.).
Noto MN, Maes M, Odebrecht Vargas Nunes S, Ota VK, Rossaneis AC, Verri Jr WA, Cordeiro Q, Iole Belangero S, Gadelha A, Affonseca Bressan R, Noto C. Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis Eur Neuropsychopharmacol. 2019;29(3):416-431. https://doi.org/10.1016/j.euroneuro.2018.12.008
Govorin NV, Ozornina NV, Ozornin AS. Changes in the cytokines levels in the course of psychopharmacotherapy of patients with the first psychotic episode in schizophrenia. Social and Clinical Psychiatry. 2011;21(1):20-24. (In Russ.).
Kaleda VG, Kliushnik TP, Sarmanova ZV, Otman IN, Dupin AM. Correlations between clinical and immunological parameters in endogenous psychoses with a first episode at the juvenile age. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2009;109(1):16-19. (In Russ.).
Trovão N, Prata J, VonDoellinger O, Santos S, Barbosa M, Coelho R. Peripheral biomarkers for first-episode psychosis — opportunities from the neuroinflammatory hypothesis of schizophrenia. Psychiatry Investig. 2019;16(3):177-184. https://doi.org/10.30773/pi.2018.12.19.1
Kopczynska M, Zelek W, Touchard S, Gaughran F, Di Forti M, Mondelli M, Murray R, O’Donovan MC, PaulMorgan B. Complement system biomarkers in first episode psychosis. Schizophrenia Research. 2019;204:16-22. https://doi.org/10.1016/j.schres.2017.12.012
Klyushnik TP, Siryachenko TM, Brusov OS, Sarmanova ZV, Otman IN, Dupin AM, Sokolov PE. The dynamics of the content of antibodies to neuroantigens in the blood serum of patients with schizophrenia during therapy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(8):61-64. (In Russ.).
Zozulya SA, Siryachenko TM, Kaleda VG, Dupin AM, Omelchenko MA, Otman IN, Kliushnik TP. The state of the immune system in endogenous mental diseases with pronounced affective disorders. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(12):63-67. (In Russ.).
Pollak TA, Rogers JP, Nagele RG, Peakman M, Stone JM, Anthony S, David AS, McGuire P. Antibodies in the diagnosis, prognosis, and prediction of psychotic disorders. Schizophrenia Bulletin. 2019;45(1):233-246. https://doi.org/10.1093/schbul/sby021
Zozulya SA, Sizov SV, Oleichik IV, Klyushnik TP. Clinico-psychopathological and immunological parameters of manic-delusional (including manic-paraphrenic) conditions with grandiose delusion. Social and Clinical Psychiatry. 2019;29(4):5-13. (In Russ.).
Dotsenko VL, Neshkova EA, Yarovaya GA. Detection of human leukocyte elastase from the complex with plasma α1-proteinase inhibitor on the basis of its enzyme activity with a synthetic substrate. Vopr Med Chem. 1994;40:3:20-25. (In Russ.).
Nartikova VF, Paskhina TS. A unified method for assay of human serum (plasma) α1-antitrypsin and α2-macroglobulin activity. Vopr Med Chem. 1979;25(4):494-499. (In Russ.).
Stockey RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999;160(5):49-52. https://doi.org/10.1164/ajrccm.160.supplement_1.13
Korkmaz B, Horwitz MS, Jenne DE, Gauthier F. Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases. Pharmacol Rev. 2010;62(4):726-759. https://doi.org/10.1124/pr.110.002733
Gettins PG. Serpin structure, mechanism, and function. Chem Rev. 2002;102(12):4751-4804. https://doi.org/10.1021/cr010170+
Sanders AR, Drigalenko EI, Duan J, Moy W, Freda J, Goring H, Gejman PV. Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis. Transl Psychiatry. 2017;7(4):e1093. https://doi.org/10.1038/tp.2017.47
Zozulya SA, Oleichik IV, Androsova LV, Otman IN, Sarmanova ZV, Stolyarov SA, Bizyaeva AS, Yunilainen OA, Klyushnik TP. Monitoring trend of endogenous psychoses by immunological parameters. Mental Health. 2017;1:11-18 (In Russ.).